Atossa Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Atossa Therapeutics, Inc. (ATOS), a Delaware corporation, filed this Current Report on Form 8-K on September 18, 2026. The company is headquartered in Seattle, Washington, and its common stock trades on the Nasdaq Capital Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the release of a corporate presentation.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The report references an attached corporate presentation (Exhibit 99.1) for updated information.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure regarding an updated corporate presentation made available on September 18, 2026. The text explicitly states that the information in this report and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, risks, or contingencies are enumerated in the filing text itself.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Corporate Presentation Dated September 18, 2026) for the actual business updates and financial context.
- Confirm that the information in the presentation is not incorporated by reference into other regulatory filings.
- Verify the company's current status on the Nasdaq Capital Market under the symbol ATOS.